This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Brain cancer

Fibroblast growth factor receptor 1 (FGFR1; CD331)

Studies in mice and in patient samples suggest inhibiting FGFR1 could be useful for treating a subset of pediatric gliomas that have genomic alterations in the target. Whole-genome sequencing identified duplications within FGFR1 in 2 of 39 pediatric gliomas. In mice, transplantation of astrocytes expressing the altered form of FGFR1 led to tumor development, whereas transplantation of astrocytes expressing wild-type FGFR1 did not. Next steps could include testing the effects of FGFR1 inhibitors in mouse models for glioma with the alteration.
At least six selective FGFR1 inhibitors are in Phase II testing or earlier to treat various cancers.

SciBX 6(17); doi:10.1038/scibx.2013.409
Published online May 2, 2013

Patent and licensing status unavailable

Zhang, J. et al. Nat. Genet.;
published online April 14, 2013;
doi:10.1038/ng.2611
Contact: David W. Ellison,
St. Jude Children's Research Hospital, Memphis, Tenn.
e-mail:
david.ellison@stjude.org